Systemic clinical-grade recombinant decorin reduces disease burden and fibrosis in advanced recessive dystrophic epidermolysis bullosa
Christine Gretzmeier, Bing Hang, Gerhard Sengle, Christopher Phillips, Ben Buer, Sarah Fletcher, Arseniy Belov, Gregory Bleck, Ian J Collins, Jürgen Brinckmann, Mark P de Souza, Hal Landy, Alexander Nyström · 2026
Read Systemic clinical-grade recombinant decorin reduces disease burden and fibrosis in advanced recessive dystrophic epidermolysis bullosa by Christine Gretzmeier, Bing Hang, Gerhard Sengle, Christopher Phillips, Ben Buer, Sarah Fletcher, Arseniy Belov, Gregory Bleck, Ian J Collins, Jürgen Brinckmann, Mark P de Souza, Hal Landy, Alexander Nyström (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13175769.txt.
Description
Christine Gretzmeier and co-authors test a lab-made version of decorin, a natural protein that limits scarring, as a treatment for a severe skin disease. Their 2026 study targets recessive dystrophic epidermolysis bullosa, where fragile skin blisters and scars over time. The scarring is disabling and raises the risk of aggressive skin cancers.
The team scaled up production of a clinical-grade form of the protein. Given by vein to mice with advanced disease, it gathered in skin and other injured sites and eased disease signs. It also curbed a key scarring signal in tissues. The work supports decorin as a candidate therapy for these patients. The authors also mapped how the protein changed the skin's collagen network.
Catalog record
| CREATOR | Christine Gretzmeier, Bing Hang, Gerhard Sengle, Christopher Phillips, Ben Buer, Sarah Fletcher, Arseniy Belov, Gregory Bleck, Ian J Collins, Jürgen Brinckmann, Mark P de Souza, Hal Landy, Alexander Nyström |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |